Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results.
The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide.
Wiley talks through these results which show 19% YoY revenue growth in the quarter to $49.3m, with a rise in full year revenue guidance to $180m - $182m.